Teva looking to build its drug delivery capabilities, acquires Microdose therapeutx for $165 million

Founded in 1998, MicroDose Therapeutx is a private pharmaceutical company successfully pioneering the creation of next-generation products utilizing its proprietary drug delivery technologies. In the pipeline, its Dry Powder Inhaler, Dry Powder Nebulizer, PolyCap™ systems, and Needlefree technologies promise to dramatically improve efficacy and compliance. Using these novel drug delivery techneques, MicroDose’s is targeting to improve the quality of life for patients suffering from debilitating diseases including asthma, COPD, RSV, IBS-C, and constipation.